Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Chief Medical Officer | September 01, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date September 01, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 380,190 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 58,850 · Balance 380,190 F1: The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2036-09-01 | Direct | 116,150 |
Reported balance
After 2026-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-01 · Grant · Acquired 116,150 · Balance 116,150 F2: The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027.
F2: The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 1, 2026 21:24 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 116,150 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0001997710-26-000004 · form4-09012026_090929.xml · derivative · entry 2 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,150 Underlying: Common Stock · 116,150 shares Expires 2036-09-01 F2 · derivative.exercise_date: The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 21:24 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 58,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001997710-26-000004 · form4-09012026_090929.xml · nonDerivative · entry 1 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,190 F1 · shares: The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 160,944 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001193125-26-088154 · ownership.xml · derivative · entry 2 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,944 Underlying: Common Stock · 160,944 shares Expires 2036-03-02 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 89,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088154 · ownership.xml · nonDerivative · entry 1 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,340 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:47 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 20,401 | $5.06 | $103,229.06 |
DisclosureSEC source: 0001193125-26-055496 · ownership.xml · nonDerivative · entry 1 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,284 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2025 Filed Nov 17, 2025 22:56 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 17,109 | $5.42 | $92,730.78 |
DisclosureSEC source: 0001193125-25-284878 · ownership.xml · nonDerivative · entry 1 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,685 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.42 to $5.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 00:30 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 2,534 | $7.75 | $19,638.50 |
DisclosureSEC source: 0000950170-25-022653 · ownership.xml · nonDerivative · entry 1 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,794 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:51 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 79,365 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0000950170-25-013828 · ownership.xml · derivative · entry 2 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,365 Underlying: Common Stock · 79,365 shares Expires 2035-02-02 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 3, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:51 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 120,635 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013828 · ownership.xml · nonDerivative · entry 1 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,328 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 02:06 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 11,822 | $9.36 | $110,663.38 |
DisclosureSEC source: 0000950170-24-128206 · ownership.xml · nonDerivative · entry 1 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,693 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.36 to $9.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:01 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 41,485 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0000950170-24-010461 · ownership.xml · derivative · entry 2 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,485 Underlying: Common Stock · 41,485 shares Expires 2034-01-31 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:01 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 28,515 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-010461 · ownership.xml · nonDerivative · entry 1 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,515 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2025, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:04 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $8.97 | $0.00 |
DisclosureSEC source: 0000950170-23-058900 · ownership.xml · derivative · entry 2 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-10-31 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on October 16, 2024 with the remainder vesting thereafter in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:04 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 135,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-058900 · ownership.xml · nonDerivative · entry 1 Hopkins Janet Jill · CIK 0001997710 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Company's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Company's common stock. These RSUs vest in four substantially equal annual installments beginning on November 15, 2024, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.